



Catalyze In Vivo Gene Therapy EOI - Version 1 - 2026.08.20

Applicant Last Name: _____

Project Title: _____

Date of Submission: _____

Section 1: Contact Information

Provide contact information for the principal investigator (PI) of this application. If the PI has designated a representative to submit the proposal on their behalf, please enter the designee's contact information as well.

1. Project Title: _____
2. Principal Investigator (Last Name, First Name): _____
3. Organization: _____
4. Title: _____
5. Department (or Discipline): _____
6. Street Address: _____
7. City: _____
8. State: _____
9. Zip code: _____
10. PI email address: _____
11. PI telephone number: _____
12. Name and contact information for corresponding organizational representative, if not the PI:

13. How did you learn about Catalyze? (Select all that apply):

- | | |
|---|--|
| ☐ NIH/NHLBI website | ☐ My technology transfer office |
| ☐ NHLBI Catalyze website | ☐ Scientific conference or news article |
| ☐ NIH Translational Program(s) | ☐ NIH Program Officer |
| ☐ Catalyze event | ☐ Other (Please specify): _____ |
| ☐ My institution/department | |



Section 2: PI Demographic Profile

Your responses to the following questions allow the Catalyze Coordinating Center to better understand the demographic profile of investigators interested in Catalyze award programs. Your responses to these questions have no influence on proposal selection and will not be shared with reviewers.

14. Position or title: _____
15. Terminal Degree: _____
16. Year of Terminal Degree (or Expected Completion Year): _____
17. Has your professional experience to date been characterized by any of the following?
Select all that apply:
- ☐ Been granted a copyright, patent, or trademark
 - ☐ A patent has been issued
 - ☐ Licensed your technology to another party
 - ☐ Applied for funding from a translational research, proof-of-concept, or commercialization support program—other than Catalyze
 - ☐ Received funding from a translational research, proof-of-concept, or commercialization support program—other than Catalyze
 - ☐ Founded a start-up company

Section 3: Technology Profile

Provide the following information about the project for which Catalyze assistance is sought.

18. What barrier does your concept address (select one):
- ☐ Gaps in translating in vitro models for in vivo outcomes
 - ☐ Translating humanized mouse models to human studies
 - ☐ Uncertain immune tolerance to foreign therapeutic proteins
 - ☐ Niche-specific intercellular crosstalk absent in existing models
 - ☐ Other (50-word limit)
19. Type of project (select up to 2):
- | | |
|--|--|
| ☐ Novel viral platforms | ☐ Targeted Lipid Nanoparticle (LNP) Platforms |
| ☐ Non-viral delivery systems | ☐ Translational models or assays |
| ☐ Immune evasion technologies | ☐ Other (50-word limit) |
| ☐ Gene editing systems | _____ |



Catalyze In Vivo Gene Therapy EOI - Version 1 - 2026.08.20

20. What is the specific technology or product (50-word limit)?

21. Indicate the status of intellectual property protection for this technology

- ☐ No invention disclosure filed with technology transfer office (or equivalent)
- ☐ Invention disclosure filed with TTO (or equivalent)
- ☐ A patent application has been submitted
- ☐ A trademark has been registered
- ☐ A copyright has been granted
- ☐ Patent has been issued

22. **Project Description.** In 1,000 words or less, please provide an overall description of your project **and how it ties into your response for what barrier your concept addresses** (in question 18).

Include the following:

- Project purpose or objective
 - Details of any preliminary studies conducted
 - Concise description of the proposed studies
 - Proposed high level milestones
-

Section 4: Prior Technology Development Support

The following questions request information about the funding and translational program support history for the technology to be developed under the proposed project. Please provide information about NIH and non-NIH support. Please also indicate whether the principal investigator and/or the technology have been supported by any NIH translational programs.

23. Were any earlier translational or product development stages supported by any of the following NIH-sponsored translational programs? (select all that apply):

- ☐ Bioengineering for HLBS
- ☐ CADET II
- ☐ Catalyze - Product Definition
- ☐ Catalyze - Preclinical
- ☐ Catalyze - Regulatory
- ☐ Excellence in Hemoglobinopathies
- ☐ Large Animal Blood Disease Core
- ☐ Molecular Imaging of the Lung
- ☐ NCAI (B-BIC, UC CAI, or NCAI-CC)
- ☐ NIGMS STTR Tech Transfer Hubs (ASCEND, DRIVEN, SHARP Hub, Southeast Xlerator Network)
- ☐ POCTRN (CAPCat)
- ☐ Preclinical GTPR
- ☐ Preclinical PACT
- ☐ Preclinical SMARTT
- ☐ Pulmonary Vascular-RV Axis
- ☐ REACH 2015 (UofL ExCITE, MN-REACH, or LIBH)
- ☐ REACH 2019 (KYNETIC, MBarC, ROI, CO-SPARK, or WE-REACH)
- ☐ SBIR/STTR
- ☐ Thrombotic and Hemostatic Centers
- ☐ tPPG
- ☐ Transformative Platforms
- ☐ VITA
- ☐ None of the above
- ☐ Other (Please provide name of NIH opportunity or program): _____